These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 5985965)

  • 21. [COMPARATIVE STUDIES ON THE TUBERCULOSTATIC ACTIVITY OF N-MORPHOLINOMETHYLPYRAZINAMIDE AND PYRAZINE-2-CARBOXAMIDE (PYRAZINAMIDE) IN VITRO AND IN VIVO].
    FREERKSEN E; BOENICKE R; ROSENFELD M
    Arzneimittelforschung; 1963 Aug; 13():722-4. PubMed ID: 14085928
    [No Abstract]   [Full Text] [Related]  

  • 22. Tuberculosis: guidelines changed for latent TB treatment.
    AIDS Treat News; 2001 Sep; (371):3. PubMed ID: 11668976
    [No Abstract]   [Full Text] [Related]  

  • 23. [A comparative study of the chemotherapeutic efficacy of pyrazinamide and morphozinamide in experimental tuberculosis].
    Makeeva OO; Pershin GN
    Probl Tuberk; 1968; 46(9):58-62. PubMed ID: 5718430
    [No Abstract]   [Full Text] [Related]  

  • 24. [Studies on pyrazine derivatives. XVI. Antitubercular properties of compound F-369 in in vitro and in vivo studies].
    Janowiec M; Marczewska J; Stambrowska A; Foks H; Pancechowska-Ksepko D; Wrześniowska K
    Pneumonol Pol; 1985 Jan; 53(1):9-14. PubMed ID: 3925442
    [No Abstract]   [Full Text] [Related]  

  • 25. [Use of pyrazinamide as an indicator of tuberculosis epidemiology in Castilla-La Mancha].
    Criado-Alvarez JJ; Sanz Cortés J
    Rev Clin Esp; 2004 Jun; 204(6):298-302. PubMed ID: 15171890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tuberculosis and renal transplantation.
    Zaragoza RM; Hernandez A; Treviño M; Diliz HS; Alvarez L
    Transplant Proc; 1996 Dec; 28(6):3309. PubMed ID: 8962285
    [No Abstract]   [Full Text] [Related]  

  • 27. [Reevaluation studies on the chemotherapeutic effect of pyrazinamide in experimental mouse tuberculosis].
    Kondo E; Kanai K
    Kekkaku; 1985 Aug; 60(8):447-53. PubMed ID: 4068450
    [No Abstract]   [Full Text] [Related]  

  • 28. Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide.
    Gangadharam PR; Geeta N; Hsu YY; Wise DL
    Int J Tuberc Lung Dis; 1999 Jun; 3(6):515-20. PubMed ID: 10383065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies on pyrazine derivatives. Part XIII. synthesis and tuberculostatic activity of some 6-alkyl-amino- and 6-dialkylhydrazinopyrazine-2-carboxylic acids derivatives.
    Foks H; Janowiec M; Manowska W
    Pol J Pharmacol Pharm; 1978; 30(1):113-8. PubMed ID: 417305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Determination of Mycobacterium tuberculosis' sensitivity to pyrazinamide on a BACTEC-960 bacteriological analyzer].
    Irtuganova OA; Smirnova NS; Slogotskaia LV
    Probl Tuberk Bolezn Legk; 2003; (7):40-2. PubMed ID: 12939878
    [No Abstract]   [Full Text] [Related]  

  • 31. Bacteriologic basis of short-course chemotherapy for tuberculosis.
    Grosset J
    Clin Chest Med; 1980 May; 1(2):231-41. PubMed ID: 6794976
    [No Abstract]   [Full Text] [Related]  

  • 32. [Short-term treatment of tuberculosis with and without pyrazinamide in the second phase (TA-80)].
    Farga V; Valenzuela P; Yañez A; Valenzuela MT; Scheel G; Mendoza F; Torres E; Icekson I; Grinspun M; Fernández M
    Rev Med Chil; 1983 Jul; 111(7):750-4. PubMed ID: 6680460
    [No Abstract]   [Full Text] [Related]  

  • 33. [Tuberculosis of the middle ear: a rare extrapulmonary manifestation].
    Schütte W; Berghaus A; Schütte A
    Dtsch Med Wochenschr; 1996 Dec; 121(49):1551. PubMed ID: 8998926
    [No Abstract]   [Full Text] [Related]  

  • 34. [THE CAUSATIVE RELATION BETWEEN THE TUBERCULOSTATIC EFFECTIVENESS OF MORPHAZINAMIDE AND ITS INSTABILITY].
    BOENICKE R
    G Ital Chemioter; 1963; 10():190-5. PubMed ID: 14079401
    [No Abstract]   [Full Text] [Related]  

  • 35. [Tuberculostatic active N,N'-diarylthioureas. 2].
    Wagner WH; Winkelmann E
    Arzneimittelforschung; 1969 May; 19(5):719-30. PubMed ID: 4895500
    [No Abstract]   [Full Text] [Related]  

  • 36. [Morphazinamide and tuberculosis].
    Dumon G; Dumon-Legre M; Brouillet-Gabriel MT; Dumon JF; Kallos SZ
    Poumon Coeur; 1966; 22(6):671-3. PubMed ID: 5916005
    [No Abstract]   [Full Text] [Related]  

  • 37. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
    Pandey R; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis.
    El-Ridy MS; Mostafa DM; Shehab A; Nasr EA; Abd El-Alim S
    Int J Pharm; 2007 Feb; 330(1-2):82-8. PubMed ID: 17049192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuberculosis presenting as immune thrombocytopenic purpura.
    Spedini P
    Haematologica; 2002 Feb; 87(2):ELT09. PubMed ID: 11836186
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
    Danckwerts MP; Ebrahim S; Pillay V
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.